Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CTR20262768 20-valent Pneumococcal Conjugate Vaccine(Pfizer) Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20262768 20-valent Pneumococcal Conjugate Vaccine(Pfizer) Pneumonia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
CTR20262768 clinical trial report covering 20-valent Pneumococcal Conjugate Vaccine(Pfizer), Phase 3, endpoints, sponsor, geography, readout timing and develo
Read →
NCT07712523 QY-201 Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07712523 QY-201 Nonsegmental vitiligo Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07712523 clinical trial report covering QY-201, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07710638 Ivermectin Warts Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07710638 Ivermectin Warts Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710638 clinical trial report covering Ivermectin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07710248 Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07710248 Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710248 clinical trial report covering Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen), Phase 2, endpoints, sponsor, geography, readout t
Read →
NCT07709780 Apixaban Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07709780 Apixaban Thrombosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07709780 clinical trial report covering Apixaban, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07710885 Futibatinib Advanced biliary tract cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07710885 Futibatinib Advanced biliary tract cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710885 clinical trial report covering Futibatinib, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07711470 Albumin-Bound Paclitaxel Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07711470 Albumin-Bound Paclitaxel Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07711470 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07709910 Ribupatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07709910 Ribupatide Obesity Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07709910 clinical trial report covering Ribupatide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07709897 Fosrolapitant Postoperative Nausea and Vomiting Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07709897 Fosrolapitant Postoperative Nausea and Vomiting Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07709897 clinical trial report covering Fosrolapitant, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07710118 Ceftriaxone Sodium Gonorrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07710118 Ceftriaxone Sodium Gonorrhea Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710118 clinical trial report covering Ceftriaxone Sodium, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07711158 SR-604 Factor VII Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07711158 SR-604 Factor VII Deficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07711158 clinical trial report covering SR-604, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07710157 Obinutuzumab Nephrosis, Lipoid Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07710157 Obinutuzumab Nephrosis, Lipoid Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
21 July 2026
NCT07710157 clinical trial report covering Obinutuzumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Read →